Preview

Медицинский Совет

Расширенный поиск

НОВАЯ СТРАТЕГИЯ ЛЕКАРСТВЕННОГО ЛЕЧЕНИЯ ЛЮМИНАЛЬНОГО HER2-НЕГАТИВНОГО МЕТАСТАТИЧЕСКОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.21518/2079-701X-2017-6-30-37

Полный текст:

Аннотация

Статья посвящена новому пероральному таргетному препарату палбоциклибу и его месту в терапии эстроген-рецептор-позитивного HER2-негативного метастатического рака молочной железы. Последовательная эндокринотерапия является предпочтительным видом лечения у пациенток этой подгруппы, т.к. существенно улучшает клинические исходы заболевания. Но способность опухоли демонстрировать приобретенную, а иногда и исходную гормонорезистентность приводит рано или поздно к прогрессированию заболевания. Открытие роли циклин-зависимых киназ (CDK) в активации пролиферации опухоли и последующее создание первого ингибитора CDK 4-го и 6-го типов палбоциклиба позволило принципиально изменить сложившуюся ситуацию: результаты клинического изучения комбинаций палбоциклиба с летрозолом или фулвестрантом продемонстрировали двукратное увеличение медианы выживаемости без прогрессирования болезни по сравнению с одной гормонотерапией. Эта стратегия, названная экспертами «терапией прорыва», сочетает в себе доказанную эффективность, хорошую переносимость, позволяет поддерживать высокое качество жизни и должна использоваться у больных с ЭР-позитивным HER2-негативным метастатическим раком молочной железы.

Об авторе

Е. В. АРТАМОНОВА
Российский онкологический научный центр им. Н.Н. Блохина
Россия
д.м.н.


Список литературы

1. Злокачественные заболевания в России в 2015 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М., 2017. 250 с.

2. Состояние онкологической помощи населению России в 2015 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. М., 2016. 236 с.

3. Pan H, Gray R& G, Davies Ch et al. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). ASCO 2016, J Clin Oncol, 2016, 34(suppl): abstr 505.

4. Saad E, Katz A, Machado K and Buyse M. Post-Progression Survival (PPS) and Overall Survival (OS) According to Treatment Type in Contemporary Phase III Trials in Advanced Breast Cancer (ABC). SABCS 2009, Abstr 5116.

5. Dawood S, Broglio K, Gonzalez-Angulo AM, et al: Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol, 2008, 26: 4891-4898.

6. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docum ent/acspc-029771.pdf].

7. DeVita V, Lawrence T, Rosenberg S et al. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of oncology. 8thed Philadelphia. J.B. Lippincott, 2008. P. 1634.

8. Perou CM. Molecular Stratification of Triple-Negative Breast Cancer. The Oncologist, 2011, 16(suppl 1): 61-70.

9. Rugo HS, Rumble RB, Macrae E et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: Americane Society of Clinical Oncology guideline. JCO, 2016. doi: 10.1200/JCO.2016.67.1487.

10. Wilcken N et al. Cochrane Database Syst Rev, 2003, 2: CD002747.

11. Llombart-Cussac A, Pivot XB, Biganzoli L et al. A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. ASCO 2013. J Clin Oncol, 2013, 31(suppl): abstr 555.

12. Cardoso F et al. Ann Oncol, 2014 Oct, 25(10): 1871-88.

13. Mauri D, Pavlidis N, Polysos NP and Ioannidis JPI. Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. JNCI, 2006, 98(18): 1285-1291.

14. Bonneterre J. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. JCO, 2000, 18: 3748-3757.

15. Mouridsen H, Gershanovich M, Sun Y et al. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group. JCO, 2001, 19(10): 2596-2606.

16. Mouridsen H, Gershanovich M, Sun Y et al. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group. JCO, 2003, 21(16): 2101-2109.

17. Robertson JFR, Lindemann JPO, Llombart-Cussac A et al. A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the «FIRST» study. Presented at: 33rd Annual San Antonio Breast Cancer Symposium, Dec 8-12, 2010, San Antonio, TX, abstr. S1-3.

18. Osborne CK, Pippen J, Jones SE et al. Double-Bl ind, Randomi zed Tr ial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With

19. Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial. JCO, 2002, 20(16): 3386-3395.

20. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Clin Oncol, 2002, 20(16): 3396-3403.

21. Chia S, Gradishar W, Mauriac L et al. Doubleblind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer:results from EFECT. J Clin Oncol, 2008, 26(10): 1664-1670.

22. Steele N, Zekri J, Coleman R et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast, 2006, 15: 430-436.

23. Carlini P, Michelotti A, Ferretti G et al. Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients. Cancer Investigation, 2007, 25: 102-105.

24. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol, 2000, 18: 2234-2244.

25. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med, 2012, 366: 520-29.

26. http://www.nobelprize.org/nobel_prizes/medicine/laureates/2001/?google_referrer = mail.ru.

27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144: 646-–74.

28. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490: 61-70.

29. Hirama T and H. Phillip Koeffler. Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer. Blood, 1995, 86: 841-854.

30. Fry D et al. Specific Inhibition of cyclindependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics, 2004, 3: 1427-1437.

31. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene, 2014, 33: 1890-903.

32. Finn RS et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res, 2009, 11(5): R77.

33. Lamb R, Lehn S, Rogerson L, Clarke RB, Landberg G. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle, 2013, 12(15): 2384-2394.

34. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as firstline treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol, 2015, 16(1): 25-35.

35. Finn RS, Crown JP, Ettl J et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2- negative, advanced breast cancer: expanded analyses of subgroups from randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Research, 2016,; 18: 67. DOI 10.1186/s13058-016-0721-5.

36. Finn RS, Martin M, Rugo HS et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). JCO, 2016, 34(suppl): abstr. 507.

37. Turner NC, Ro J, Andre F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med, 2015, 373(3): 209-19. doi: 10.1056/NEJMoa1505270.

38. Cristofanilli M, Turner NC et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2- negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17: 425- 39.

39. Cristofanilli M, Bondarenko I, Ro J et al. PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy – confirmed efficacy and safety. Presented at SABCS 2015, San Antonio, Texas, USA (Poster 4- 13-01).

40. Turner NC, Jiang Y, O’Leary B et al. Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). J Clin Oncol, 2016, 34(suppl): abstr 512.

41. Harbeck N, Iyer S, Cristofanilli M et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann. Oncol., 2016, 27: 1047-1054.

42. Verma S, Bartlett CH, Schnell P et al. Palbociclib in Combination With Fulvestrant inWomen With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From aMulticenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologyst, 2016, 21: 1-11.

43. Diéras V, Rugo HS S, Gelmon K, et al. Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies. Poster presented at SABCS 2016 (Abstract P4-22-07).


Для цитирования:


АРТАМОНОВА Е.В. НОВАЯ СТРАТЕГИЯ ЛЕКАРСТВЕННОГО ЛЕЧЕНИЯ ЛЮМИНАЛЬНОГО HER2-НЕГАТИВНОГО МЕТАСТАТИЧЕСКОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ. Медицинский Совет. 2017;(6):30-37. https://doi.org/10.21518/2079-701X-2017-6-30-37

For citation:


ARTAMONOVA E.V. NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER. Medical Council. 2017;(6):30-37. (In Russ.) https://doi.org/10.21518/2079-701X-2017-6-30-37

Просмотров: 163


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)